Jubilant and AstraZeneca successful in delivery of early milestones in pain drug accord

Jubilant Biosys, a Bengaluru-based subsidiary of India’s Jubilant Life Sciences, and Anglo-Swedish drug major AstraZeneca (LSE: AZN), yesterday announced another successful delivery of an early stage milestone in the pain therapeutic area, under a collaboration deal signed in 2009 and triggering an undisclosed payment to the Indian firm.

The collaboration, initiated two years ago in the neuroscience therapeutic area, has now expanded to cardiovascular and metabolic diseases and focuses on the delivery of a steady stream of preclinical outcomes to AstraZeneca by Jubilant. AstraZeneca owns the compounds developed under the collaboration with worldwide development and commercialization rights. Jubilant derives research funding and success-based development and commercialization milestones.

Commenting on this development, Sri Mosur, chief executive and president, global drug discovery and development at Jubilant, said: "We are pleased that we have delivered outcomes and early success to the portfolio efforts at AstraZeneca. This is the result of excellent collaboration between scientists at Jubilant and AstraZeneca.